151
|
Huang Y, Qin S, Gu X, Zheng M, Zhang Q, Liu Y, Cheng C, Huang K, Peng C, Ju S. Comprehensive Assessment of Serum hsa_circ_0070354 as a Novel Diagnostic and Predictive Biomarker in Non-small Cell Lung Cancer. Front Genet 2022; 12:796776. [PMID: 35096013 PMCID: PMC8793632 DOI: 10.3389/fgene.2021.796776] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2021] [Accepted: 11/24/2021] [Indexed: 12/12/2022] Open
Abstract
Background: More and more studies have shown that circular RNAs (circRNAs) play an essential role in the occurrence and development of tumors. Hence, they can be used as biomarkers to assist in diagnosing tumors. This study focuses on exploring the role of circular RNA (hsa_circ_0070354) in the diagnosis and prognosis of non-small cell lung cancer (NSCLC). Materials and Methods: First of all, high-throughput sequencing was used to find the difference in the expression of circular RNA between NSCLC and adjacent tissues. The circRNAs with higher differences in expression were selected to verify their expressions in tissues, cells, and serum using qRT-PCR. Secondly, the hsa_circ_0070354 with a significant difference was chosen as the research goal, and the molecular properties were verified by agarose gel electrophoresis and Sanger sequencing, etc. Then, actinomycin D and repeated freeze-thaw were used to explore the stability and repeatability of hsa_circ_0070354. Finally, the expression of hsa_circ_0070354 in serum of 133 patients with NSCLC and 97 normal donors was detected, and its sensitivity, specificity, and prognosis as tumor markers were statistically analyzed. Results: Hsa_circ_0070354 was highly expressed in tissues, cells, and serum of NSCLC, and it has the characteristics of sensitivity, stability, and repeatability. The ROC curve indicates that hsa_circ_0070354 is superior to conventional tumor markers in detecting NSCLC, and the combined diagnosis is of more significance in the diagnosis. The high expression of hsa_circ_0070354 is closely related to the late-stage, poor differentiation of the tumor and the short survival time of the patients, which is an independent indicator of poor prognosis. Conclusion: Hsa_circ_0070354 is not only a novel sensitive index for the diagnosis of NSCLC but also a crucial marker for bad biological behavior.
Collapse
Affiliation(s)
- Yuejiao Huang
- Department of Medical Oncology, Affiliated Hospital of Nantong University, Nantong, China.,Medical School of Nantong University, Nantong, China
| | - Shiyi Qin
- Medical School of Nantong University, Nantong, China.,Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, China
| | - Xinliang Gu
- Medical School of Nantong University, Nantong, China.,Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, China
| | - Ming Zheng
- Medical School of Nantong University, Nantong, China.,Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, China
| | - Qi Zhang
- Medical School of Nantong University, Nantong, China.,Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, China
| | - Yupeng Liu
- Department of Thoracic Surgery, Affiliated Tumor Hospital of Nantong University, Nantong, China
| | - Chun Cheng
- Department of Thoracic Surgery, Affiliated Tumor Hospital of Nantong University, Nantong, China
| | - Kaibin Huang
- Department of General Surgery, Nantong Haimen People's Hospital, Nantong, China
| | - Chunlei Peng
- Department of Medical Oncology, Affiliated Tumor Hospital of Nantong University, Nantong, China
| | - Shaoqing Ju
- Medical School of Nantong University, Nantong, China.,Department of Laboratory Medicine, Affiliated Hospital of Nantong University, Nantong, China
| |
Collapse
|
152
|
Chen M, Yang L, Yu H, Yu H, Wang S, Tian L, Liu S. Early Palliative Care in Patients With Non-Small-Cell Lung Cancer: A Randomized Controlled Trial in Southwest China. Am J Hosp Palliat Care 2022; 39:1304-1311. [PMID: 35088602 DOI: 10.1177/10499091211072502] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
PURPOSE Effective interventions to improve prognosis in non-small-cell lung cancer (NSCLC) are urgently needed. We assessed the effect of the early integration of interdisciplinary palliative care (based on WARM model) for patients with NSCLC on the quality of life (QoL), psychological state, cancer pain and nutritional status. METHODS In this randomized controlled trial, 120 newly diagnosed NSCLC patients were enrolled and randomly assigned (1:1) to the combined early palliative care (CEPC) group integrated with standard oncologic care or standard oncological care (SC) group. QoL and psychological state were assessed at baseline and at 24 weeks by Functional Assessment of Cancer Therapy-Lung (FACT-L) scale, the Hospital Anxiety and Depression Scale (HADS) and Patient Health Questionnaire-9 (PHQ-9), respectively. Cancer nutritional and pain status were assessed with the use of the Patient-Generated Subjective Global Assessment (PG-SGA) and Numerical Rating Scale (NRS), respectively. The primary outcome was the change in the quality of life, psychological state and nutritional status at 24 weeks. Analysis was by intention to treat. RESULTS 120 patients were enrolled: 60 in CEPC group (38 completed) and 60 in the SC group (32 completed). CEPC group had a better QoL than SC group (P < .05). In addition, fewer patients in the CEPC group than in the SC group had depressive (P = .005) symptoms. Furthermore, patients in CEPC group had a better nutritional status than SC group (P = .001). CONCLUSION Among patients with non-small-cell lung cancer, early palliative care led to significant improvements in quality of life, psychological state and nutritional status.
Collapse
Affiliation(s)
- Mengting Chen
- 605425Chongqing University Cancer Hospital, Chongqing, P.R. China
| | - Liejun Yang
- 605425Chongqing University Cancer Hospital, Chongqing, P.R. China
| | - Huiqing Yu
- 605425Chongqing University Cancer Hospital, Chongqing, P.R. China
| | - Huijuan Yu
- College of Arts, 605425Chongqing University, Chongqing, P.R. China
| | - Sixiong Wang
- 605425Chongqing University Cancer Hospital, Chongqing, P.R. China
| | - Ling Tian
- 605425Chongqing University Cancer Hospital, Chongqing, P.R. China
| | - Shihong Liu
- 605425Chongqing University Cancer Hospital, Chongqing, P.R. China
| |
Collapse
|
153
|
Brest P, Mograbi B, Hofman P, Milano G. COVID-19 vaccination and cancer immunotherapy: should they stick together? Br J Cancer 2022; 126:1-3. [PMID: 34799696 PMCID: PMC8603902 DOI: 10.1038/s41416-021-01618-0] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2021] [Revised: 09/29/2021] [Accepted: 10/27/2021] [Indexed: 02/08/2023] Open
Abstract
The combination of COVID-19 vaccination with immunotherapy by checkpoint inhibitors in cancer patients could intensify immunological stimulation with potential reciprocal benefits. Here, we examine more closely the possible adverse events that can arise in each treatment modality. Our conclusion is that caution should be exercised when combining both treatments.
Collapse
Affiliation(s)
- Patrick Brest
- grid.417812.90000 0004 0639 1794Université Côte d’Azur, CNRS, Inserm, IRCAN, Centre Antoine Lacassagne, FHU-OncoAge, 06189 Nice, France
| | - Baharia Mograbi
- grid.417812.90000 0004 0639 1794Université Côte d’Azur, CNRS, Inserm, IRCAN, Centre Antoine Lacassagne, FHU-OncoAge, 06189 Nice, France
| | - Paul Hofman
- grid.417812.90000 0004 0639 1794Université Côte d’Azur, CNRS, Inserm, IRCAN, Centre Antoine Lacassagne, FHU-OncoAge, 06189 Nice, France ,grid.460782.f0000 0004 4910 6551Université Côte d’Azur, Laboratory of Clinical and Experimental Pathology, CHU-Nice, FHU OncoAge, Hospital-Integrated Biobank (BB-0033-00025), Nice, France
| | - Gerard Milano
- Université Côte d'Azur, Centre Antoine Lacassagne, EA7497, Nice, France.
| |
Collapse
|
154
|
Li G, Luo Q, Wang X, Zeng F, Feng G, Che G. Deep learning reveals cuproptosis features assist in predict prognosis and guide immunotherapy in lung adenocarcinoma. Front Endocrinol (Lausanne) 2022; 13:970269. [PMID: 36060936 PMCID: PMC9437348 DOI: 10.3389/fendo.2022.970269] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/15/2022] [Accepted: 07/25/2022] [Indexed: 12/12/2022] Open
Abstract
BACKGROUND Cuproptosis is a recently found non-apoptotic cell death type that holds promise as an emerging therapeutic modality in lung adenocarcinoma (LUAD) patients who develop resistance to radiotherapy and chemotherapy. However, the Cuproptosis' role in the onset and progression of LUAD remains unclear. METHODS Cuproptosis-related genes (CRGs) were identified by a co-expression network approach based on LUAD cell line data from radiotherapy, and a robust risk model was developed using deep learning techniques based on prognostic CRGs and explored the value of deep learning models systematically for clinical applications, functional enrichment analysis, immune infiltration analysis, and genomic variation analysis. RESULTS A three-layer artificial neural network risk model was constructed based on 15 independent prognostic radiotherapy-related CRGs. The risk model was observed as a robust independent prognostic factor for LUAD in the training as well as three external validation cohorts. The patients present in the low-risk group were found to have immune "hot" tumors exhibiting anticancer activity, whereas the high-risk group patients had immune "cold" tumors with active metabolism and proliferation. The high-risk group patients were more sensitive to chemotherapy whereas the low-risk group patients were more sensitive to immunotherapy. Genomic variants did not vary considerably among both groups of patients. CONCLUSION Our findings advance the understanding of cuproptosis and offer fresh perspectives on the clinical management and precision therapy of LUAD.
Collapse
Affiliation(s)
- Gang Li
- Department of Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu, China
- Department of Thoracic Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
- Sichuan Translational Medicine Research Hospital, Chinese Academy of Sciences, Chengdu, China
| | - Qingsong Luo
- Department of Thoracic Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
- Sichuan Translational Medicine Research Hospital, Chinese Academy of Sciences, Chengdu, China
| | - Xuehai Wang
- Department of Thoracic Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
- Sichuan Translational Medicine Research Hospital, Chinese Academy of Sciences, Chengdu, China
| | - Fuchun Zeng
- Department of Thoracic Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
- Sichuan Translational Medicine Research Hospital, Chinese Academy of Sciences, Chengdu, China
| | - Gang Feng
- Department of Thoracic Surgery, Sichuan Provincial People’s Hospital, University of Electronic Science and Technology of China, Chengdu, China
- Sichuan Translational Medicine Research Hospital, Chinese Academy of Sciences, Chengdu, China
| | - Guowei Che
- Department of Thoracic Surgery, West-China Hospital, Sichuan University, Chengdu, China
- *Correspondence: Guowei Che,
| |
Collapse
|
155
|
Yamamoto H, Togashi Y. Programmed Death-Ligand 1-Rich Premetastatic Niche in Adjuvant Chemotherapy. J Thorac Oncol 2021; 17:10-12. [PMID: 34930604 DOI: 10.1016/j.jtho.2021.10.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/17/2021] [Accepted: 10/20/2021] [Indexed: 11/18/2022]
Affiliation(s)
- Hiromasa Yamamoto
- Department of Thoracic Surgery, Okayama University Hospital, Okayama, Japan
| | - Yosuke Togashi
- Department of Tumor Microenvironment, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama, Japan.
| |
Collapse
|
156
|
Conversion Surgery for Advanced Thoracic SMARCA4-Deficient Undifferentiated Tumor With Atezolizumab in Combination With Bevacizumab, Paclitaxel, and Carboplatin Treatment: A Case Report. JTO Clin Res Rep 2021; 2:100235. [PMID: 34746887 PMCID: PMC8551843 DOI: 10.1016/j.jtocrr.2021.100235] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/19/2021] [Revised: 09/10/2021] [Accepted: 09/24/2021] [Indexed: 11/21/2022] Open
Abstract
A SMARCA4-deficient undifferentiated tumor (SMARCA4-UT) is a rapidly progressing subtype of lung cancer with a poor prognosis and causes early postoperative recurrence among operable patients. In this study, we present a case of SMARCA4-UT with vertebral and chest wall invasion that successfully underwent conversion surgery after treatment with atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin. The surgical specimen comprised SMARCA4-deficient and SMARCA2-positive adenocarcinoma, confirming intratumor heterogeneity. Gene panel analysis revealed no substantial differences in mutant gene profiles among tumors and no differences in SMARCA2 mutations. Furthermore, no recurrence occurred for 9 months after surgery. Thus, this case illustrates the possibility of multidisciplinary treatment including neoadjuvant therapy with immunotherapy and conversion surgery for SMARCA4-UT.
Collapse
|
157
|
Hofman P. EGFR Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists? Cells 2021; 10:2157. [PMID: 34440926 PMCID: PMC8392580 DOI: 10.3390/cells10082157] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/06/2021] [Revised: 08/18/2021] [Accepted: 08/19/2021] [Indexed: 02/08/2023] Open
Abstract
The recent emergence of novel neoadjuvant and/or adjuvant therapies for early stage (I-IIIA) non-small cell lung carcinoma (NSCLC), mainly tyrosine kinase inhibitors (TKIs) targeting EGFR mutations and immunotherapy or chemo-immunotherapy, has suddenly required the evaluation of biomarkers predictive of the efficacy of different treatments in these patients. Currently, the choice of one or another of these treatments mainly depends on the results of immunohistochemistry for PD-L1 and of the status of EGFR and ALK. This new development has led to the setup of different analyses for clinical and molecular pathology laboratories, which have had to rapidly integrate a number of new challenges into daily practice and to establish new organization for decision making. This review outlines the impact of the management of biological samples in laboratories and discusses perspectives for pathologists within the framework of EGFR TKIs in early stage NSCLC.
Collapse
Affiliation(s)
- Paul Hofman
- Laboratory of Clinical and Experimental Pathology, CHU Nice, FHU OncoAge, Pasteur Hospital, Université Côte d’Azur, 06108 Nice, France; ; Tel.: +33-492-038-855; Fax: +33-492-8850
- CHU Nice, FHU OncoAge, Hospital-Integrated Biobank BB-0033-00025, Université Côte d’Azur, 06000 Nice, France
| |
Collapse
|
158
|
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer. Nat Commun 2021; 12:5045. [PMID: 34413300 PMCID: PMC8376947 DOI: 10.1038/s41467-021-25188-0] [Citation(s) in RCA: 36] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Accepted: 07/27/2021] [Indexed: 01/07/2023] Open
Abstract
Radiographic imaging is the standard approach for evaluating the disease involvement of lymph nodes in patients with operable NSCLC although the impact of neoadjuvant immune checkpoint inhibitors (ICIs) on lymph nodes has not yet been characterized. Herein, we present an ad hoc analysis of the NEOSTAR trial (NCT03158129) where we observed a phenomenon we refer to as “nodal immune flare” (NIF) in which patients treated with neoadjuvant ICIs demonstrate radiologically abnormal nodes post-therapy that upon pathological evaluation are devoid of cancer and demonstrate de novo non-caseating granulomas. Abnormal lymph nodes are analyzed by computed tomography and 18F-fluorodeoxyglucose positron emission tomography/computer tomography to evaluate the size and the maximum standard uptake value post- and pre-therapy in NEOSTAR and an independent neoadjuvant chemotherapy cohort. NIF occurs in 16% (7/44) of patients treated with ICIs but in 0% (0/28) of patients after neoadjuvant chemotherapy. NIF is associated with an inflamed nodal immune microenvironment and with fecal abundance of genera belonging to the family Coriobacteriaceae of phylum Actinobacteria, but not with tumor responses or treatment-related toxicity. Our findings suggest that this apparent radiological cancer progression in lymph nodes may occur due to an inflammatory response after neoadjuvant immunotherapy, and such cases should be evaluated by pathological examination to distinguish NIF from true nodal progression and to ensure appropriate clinical treatment planning. Granulomatous/sarcoid-like lesions have been reported in patients treated with immune checkpoint inhibitors (ICIs). Here the authors report the occurrence of “nodal immune flare”, an apparent radiological cancer progression in the nodes characterized by the absence of cancer and the presence of non-caseating granulomas, in patients with non-small cell lung cancer following neoadjuvant ICI treatment.
Collapse
|
159
|
Huynh C, Sorin M, Rayes R, Fiset PO, Walsh LA, Spicer JD. Pathological complete response as a surrogate endpoint after neoadjuvant therapy for lung cancer. Lancet Oncol 2021; 22:1056-1058. [PMID: 34339641 DOI: 10.1016/s1470-2045(21)00405-8] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2021] [Revised: 07/02/2021] [Accepted: 07/07/2021] [Indexed: 01/14/2023]
Affiliation(s)
- Caroline Huynh
- Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, H3A 1A3 QC, Canada; Department of Surgery, McGill University Health Centre, Montréal, QC, Canada
| | - Mark Sorin
- Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, H3A 1A3 QC, Canada; Department of Human Genetics, McGill University, Montréal, H3A 1A3 QC, Canada
| | - Roni Rayes
- Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, H3A 1A3 QC, Canada; Department of Surgery, McGill University Health Centre, Montréal, QC, Canada
| | - Pierre O Fiset
- Department of Human Genetics, McGill University, Montréal, H3A 1A3 QC, Canada; Department of Pathology, McGill University Health Centre, Montréal, QC, Canada
| | - Logan A Walsh
- Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, H3A 1A3 QC, Canada; Department of Human Genetics, McGill University, Montréal, H3A 1A3 QC, Canada.
| | - Jonathan D Spicer
- Rosalind and Morris Goodman Cancer Research Centre, McGill University, Montréal, H3A 1A3 QC, Canada; Department of Surgery, McGill University Health Centre, Montréal, QC, Canada
| |
Collapse
|
160
|
Mercier O, Barlesi F. Precision follow-up for resected non-small-cell lung cancer: is it ready for prime time? Eur J Cardiothorac Surg 2021; 60:1232-1233. [PMID: 34347068 DOI: 10.1093/ejcts/ezab357] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Olaf Mercier
- Department of Thoracic Surgery and Heart-Lung Transplantation, International Center of Thoracic Cancers, Marie Lannelongue Hospital, Université Paris-Saclay, GHPSJ, Le Plessis-Robinson, France
| | - Fabrice Barlesi
- Gustave Roussy Cancer Campus, International Center of Thoracic Cancers, Université Paris-Saclay, Villejuif, France.,Aix Marseille University, CNRS, INSERM, CRCM, Marseille, France
| |
Collapse
|
161
|
Shu CA, Cascone T. What Is Neo? Chemoimmunotherapy in the Neoadjuvant Setting for Resectable Non-Small-Cell Lung Cancer. J Clin Oncol 2021; 39:2855-2858. [PMID: 34339287 DOI: 10.1200/jco.21.01446] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/11/2022] Open
Affiliation(s)
- Catherine A Shu
- Division of Hematology/Oncology, Department of Medicine, Columbia University Medical Center, New York, NY
| | - Tina Cascone
- Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
162
|
Spicer JD. The case for peri-adjuvant therapy in early-stage lung cancer. Ann Thorac Surg 2021; 113:1616. [PMID: 34214554 DOI: 10.1016/j.athoracsur.2021.05.081] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/26/2021] [Accepted: 05/29/2021] [Indexed: 11/01/2022]
Affiliation(s)
- Jonathan D Spicer
- Associate Professor of Surgery, McGill University, Division of Thoracic and Upper Gastrointestinal Surgery, McGill University Health Center, 1650 Cedar Avenue, L8-520, Montreal, Qc, Canada H3G 1A4.
| |
Collapse
|
163
|
Antognelli C, Mandarano M, Prosperi E, Sidoni A, Talesa VN. Glyoxalase-1-Dependent Methylglyoxal Depletion Sustains PD-L1 Expression in Metastatic Prostate Cancer Cells: A Novel Mechanism in Cancer Immunosurveillance Escape and a Potential Novel Target to Overcome PD-L1 Blockade Resistance. Cancers (Basel) 2021; 13:cancers13122965. [PMID: 34199263 PMCID: PMC8232032 DOI: 10.3390/cancers13122965] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2021] [Revised: 06/09/2021] [Accepted: 06/10/2021] [Indexed: 02/07/2023] Open
Abstract
Simple Summary Metastatic prostate cancer (mPCa) is a well-known lethal condition. One of the mechanisms through which PCa cells become so aggressive is the avoidance of immune surveillance that further fosters cell growth, invasion, and migration. PD-L1/PD-1 axis plays a crucial role in inhibiting cytotoxic T cells and maintaining an immunosuppressive cancer microenvironment. Hence, targeting PD-L1/PD-1 axis represents a potential way to control mPCa. Unfortunately, mPCa patients do not respond to PD-L1/PD-1 axis blockade, focusing the research to understand the possible underpinning mechanisms. Our results provide a novel pathway taking part in cancer immunosurveillance escape and in the above-mentioned immunotherapy resistance, which provides the basis for additional studies aimed at developing novel therapeutic opportunities, possibly also in combination with antibodies blocking PD-L1/PD-1 axis. Abstract Metastatic prostate cancer (mPCa) is a disease for which to date there is not curative therapy. Even the recent and attractive immunotherapeutic approaches targeting PD-L1, an immune checkpoint protein which helps cancer cells to escape from immunosurveillance, have proved ineffective. A better understanding of the molecular mechanisms contributing to keep an immunosuppressive microenvironment associated with tumor progression and refractoriness to PD-L1 inhibitors is urgently needed. In the present study, by using gene silencing and specific activators or scavengers, we demonstrated, in mPCa cell models, that methylglyoxal (MG), a potent precursor of advanced glycation end products (AGEs), especially 5-hydro-5-methylimidazolone (MG-H1), and its metabolizing enzyme, glyoxalase 1 (Glo1), contribute to maintain an immunosuppressive microenvironment through MG-H1-mediated PD-L1 up-regulation and to promote cancer progression. Moreover, our findings suggest that this novel mechanism might be responsible, at least in part, of mPCa resistance to PD-L1 inhibitors, such as atezolizumab, and that targeting it may sensitize cells to this PD-L1 inhibitor. These findings provide novel insights into the mechanisms of mPCa immunosurveillance escape and help in providing the basis to foster in vivo research toward novel therapeutic strategies for immunotherapy of mPCa.
Collapse
Affiliation(s)
- Cinzia Antognelli
- Department of Medicine and Surgery, Bioscience and Medical Embryology Division, University of Perugia, L. Severi Square, 06129 Perugia, Italy;
- Correspondence: ; Tel.: +39-075-585-8354
| | - Martina Mandarano
- Section of Anatomic Pathology and Histology, Department of Medicine and Surgery, University of Perugia, L. Severi Square, 06129 Perugia, Italy; (M.M.); (E.P.); (A.S.)
| | - Enrico Prosperi
- Section of Anatomic Pathology and Histology, Department of Medicine and Surgery, University of Perugia, L. Severi Square, 06129 Perugia, Italy; (M.M.); (E.P.); (A.S.)
| | - Angelo Sidoni
- Section of Anatomic Pathology and Histology, Department of Medicine and Surgery, University of Perugia, L. Severi Square, 06129 Perugia, Italy; (M.M.); (E.P.); (A.S.)
| | - Vincenzo Nicola Talesa
- Department of Medicine and Surgery, Bioscience and Medical Embryology Division, University of Perugia, L. Severi Square, 06129 Perugia, Italy;
| |
Collapse
|
164
|
Lin DQ, Zhu JG, Xu XH, Xiao K, Wen XQ, Zheng QF, Zhou YH, Cai XY. Chronic Progression of Lung Cancer Recurrence After Surgery: Warning Role of Postoperative Pneumonia. Cancer Manag Res 2021; 13:7387-7398. [PMID: 34602824 PMCID: PMC8481098 DOI: 10.2147/cmar.s327646] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/02/2021] [Accepted: 09/11/2021] [Indexed: 02/05/2023] Open
Abstract
PURPOSE The association between the process of postoperative pneumonia and lung cancer recurrence remains elusive in lung cancer surgery. Herein, the association between postoperative pneumonia and lung cancer recurrence was investigated, emphasizing the warning role of postoperative specific pneumonia in primary lung cancer resection patients. METHODS The occurrence of postoperative pneumonia was assessed in 4-6 months (PPFS), 7-12 months (PPST), and lung cancer recurrence within 1 year (LRO) in 332 patients. The primary outcome was the development of PPST and LRO according to PPFS occurrence. The relevant risk factors of PPFS, PPST, and LRO were identified through multivariable regression analysis. RESULTS During follow-up, 151 (45.48%) participants experienced PPFS. Irrespective of the existing postoperative pneumonia in 1-3 months (PPOT), PPFS significantly increased the risk of PPST (P < 0.01) and LRO (P < 0.01), and persistent PPST further increased the risk of LRO (P < 0.001). The generalized estimating equation identified chemotherapy as an independent risk factor for PPFS and PPST. CONCLUSION PPFS was associated with the increased risk of PPST and LRO. Postoperative pulmonary inflammation assessed 4 months post-surgery also significantly influenced LRO development, indicating a need for close follow-up of lung inflammatory conditions to improve patient outcomes.
Collapse
Affiliation(s)
- Dong-qi Lin
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People’s Republic of China
| | - Jin-guo Zhu
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People’s Republic of China
| | - Xiao-hua Xu
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People’s Republic of China
| | - Ke Xiao
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People’s Republic of China
| | - Xu-qing Wen
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People’s Republic of China
| | - Qi-fa Zheng
- Department of Cardiothoracic Surgery, The Second Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, People’s Republic of China
| | - Yu-hua Zhou
- Nursing Department, Shantou Central Hospital, Shantou, Guangdong, People’s Republic of China
| | - Xin-ying Cai
- Clinical Research Center, Shantou Central Hospital, Shantou, Guangdong, People’s Republic of China
- Correspondence: Xin-ying Cai Clinical Research Center, Shantou Central Hospital, Wai-ma Road 114, Shantou, Guangdong, People’s Republic of ChinaTel +86 754-88903584Fax +86 754-88548117 Email
| |
Collapse
|